May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Prevention of Experimental Choroidal Neovascularization by Intravitreal Injection of Recombinant Adeno-Associated Virus (rAAV) Vector Expressing Mouse Angiostatin
Author Affiliations & Notes
  • C. Lai
    Ophthalmology, Chang Gung Memorial Hospital, Kwei-Shan, Taiwan Republic of China
  • W. Wu
    Ophthalmology, Chang Gung Memorial Hospital, Kwei-Shan, Taiwan Republic of China
  • S. Chen
    Department of Microbiology and Immunology, National Defense Medical Cente, Taipei, Taiwan Republic of China
  • M. Sun
    Department of Microbiology and Immunology, National Defense Medical Cente, Taipei, Taiwan Republic of China
  • T. Chen
    Department of Microbiology and Immunology, National Defense Medical Cente, Taipei, Taiwan Republic of China
  • R. Tsai
    Department of Microbiology and Immunology, National Defense Medical Cente, Taipei, Taiwan Republic of China
  • Y. Tsao
    Department of Microbiology and Immunology, National Defense Medical Cente, Taipei, Taiwan Republic of China
  • Footnotes
    Commercial Relationships  C. Lai, None; W. Wu, None; S. Chen, None; M. Sun, None; T. Chen, None; R. Tsai, None; Y. Tsao, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 581. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Lai, W. Wu, S. Chen, M. Sun, T. Chen, R. Tsai, Y. Tsao; Prevention of Experimental Choroidal Neovascularization by Intravitreal Injection of Recombinant Adeno-Associated Virus (rAAV) Vector Expressing Mouse Angiostatin . Invest. Ophthalmol. Vis. Sci. 2003;44(13):581.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To prevent experimental choroidal neovascularization (CNV) in a rat model with intravitreal injection of recombinant adeno-associated virus (rAAV) vector expressing mouse angiostatin. Methods: rAAV-angiostatin and control virus rAAV-lacZ were delivered in vivo by intravitreal injection on Brown Norway rats and the delivery was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR). CNV was produced by krypton laser photocoagulation 7 days after viral vector injection and was evaluated by fluorescein-dextran (FITC) angiography and histology. Apoptosis in retina was analyzed using terminal deoxynucleotidyl transferase-mediated biotin-deoxyuridine triphosphate nick and labeling assay (TUNEL). Inflammation in retina was investigated by immunohistochemistry using antibodies recognizing lymphocytes. Results: rAAV-angiostatin intravitreal injection led to sustained expression of angiostatin gene in retinal tissue. FITC angiography analysis and histology revealed significant reduction of the average sizes of CNV lesion in rAAV-angiostatin injected eyes when compared with rAAV-lacZ injected eyes at 14 and days after. As to the adverse effects, rAAV-angiostatin injection did not cause inflammation or apoptosis of cells in retina and choroid. Conclusions: In this study, we confirmed intravitral injection of rAAV-angiostatin could significantly reduce the sizes of CNV lesion. The results showed the feasibility of intravitreal injection of rAAV-angiostatin as treatment of experimental CNV.

Keywords: choroid: neovascularization • gene transfer/gene therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×